The organization headed by Health Secretary Robert F. Kennedy Jr. before he became health secretary has formally requested an agency under his purview to revoke its approvals for most of the COVID-19 vaccines available in the United States.
The shots have been manufactured under standards for emergency authorization, but are now only cleared under normal approval, the filing states. That means “they cannot remain in interstate commerce because they are, in fact, misbranded products. By law, their licenses must be revoked,” according to the petition to the Food and Drug Administration.
Pfizer and Moderna, whose vaccines utilize messenger ribonucleic acid (mRNA) technology, did not respond to requests for comment.
“This petition not only challenges COVID-19 vaccine licensure, but it sends a clear message to the FDA that it can no longer get away with licensing rushed mRNA technology under emergency standards,” Ray Flores, senior outside counsel for Children’s Health Defense, told The Epoch Times in an email. “We ask the FDA to admit that COVID-19 vaccines should never have been deemed ‘safe and effective,’ and to concede that they are actually Emergency Use Authorization vaccines that only ‘may be effective.’”
A spokesperson for Kennedy’s agency, the Department of Health and Human Services, told The Epoch Times in an email that the FDA has received the petition. The FDA is reviewing it and will respond directly to the petitioner, the spokesperson said.
Kennedy chaired Children’s Health Defense from 2015 to 2023, when he launched a bid for president. Kennedy later endorsed President Donald Trump, who named Kennedy as health secretary after winning the 2024 election.
Children’s Health Defense has regularly advocated against vaccine mandates and the use of some vaccines, asserting evidence is inadequate to support their administration.
In the new petition, Children’s Health Defense attorneys and scientists said they were focused on labeling criteria and that they were not touching on the safety or efficacy of the COVID-19 vaccines.
When the FDA first cleared shots against COVID-19 in 2020, it did so under emergency use authorization, which enables regulators to act with a lower degree of evidence under emergency conditions. To approve products, the FDA must be confident they are effective. For emergency authorization, the FDA can find that “based on the totality of the scientific evidence available, it is reasonable to believe that the product may be effective for the specified use.”
Dr. Vinay Prasad, the FDA’s top vaccine official, said in memorandums that evidence shows benefits outweigh harms for vaccinating certain populations, including children with risk factors, such as obesity.







